OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or th ...

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company” or “we”) announced that, commencing February 26, 2026, holders of the 10,000,000 units sold in the Company's initial public offering may elect to separately trade the ordinary shares and rights included in the units. Any units not separated will continue to trade on the Global Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “RFAMU,” and the separated ordinary shares and rights are expected to trade on ...

Core Viewpoint - Novo Resources Corp. is undertaking a capital raising through a proposed placement of securities to raise gross proceeds of approximately C$5,800,000 (approximately A$6,000,000) [1] Group 1: Placement Details - The Placement will consist of up to 59,100,000 units, with units priced at C$0.10 per share and Chess Depository Interests (CDIs) priced at A$0.105 per CDI [2] - Each unit will include one share and one-half of a share purchase warrant, with warrants having an exercise price of C$0.15 and expiring three years from the issue date [3] - The issue price for the units represents a 25% discount to the market price on the Toronto Stock Exchange, while the CDIs represent a 19.2% discount to the last closing price on the ASX [6] Group 2: Use of Proceeds - Proceeds from the Placement are intended to support exploration activities in the Pilbara region of Western Australia and at the Belltopper Gold Project in Victoria, as well as for general working capital [7] Group 3: Securities and Approvals - All securities issued under the Placement will be subject to a four-month hold period, and the Placement does not require shareholder approval in Australia or Canada [8] - The Lead Managers will receive up to 8,273,557 unlisted broker options, subject to shareholder approval at the Company's AGM planned for June 2026 [9] Group 4: Company Overview - Novo Resources is an Australian-based gold explorer focused on discovering standalone gold and copper projects with over 1 million ounces of development potential, covering approximately 4,160 square kilometers in the Pilbara region [14] - The company is advancing its exploration projects, including the Egina Gold Camp and the Belltopper project, and has formed a lithium joint venture with SQM in the Pilbara [15][16]

Schindellegi, Switzerland – 24 February 2026 Trifork Group AGCompany announcement no. 11/2026 Change of reporting segmentation In the upcoming Q4 and Annual Report 2025 on 27 February 2026, Trifork Group reorganizes its reporting segmentation from ‘Inspire’, ‘Build’ and ‘Run’ to two segments: ‘Products’ and ‘Services’. The former Build segment will be renamed Services, while the former Run and Inspire segments will be combined into a single segment, Products. This update reflects Trifork’s continued shift t ...

GRAND CAYMAN, Cayman Islands, Feb. 24, 2026 (GLOBE NEWSWIRE) -- SPACSphere Acquisition Corp. (the “Company”) announced today that, commencing on or about Friday, February 27, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Class A ordinary shares, warrants, and rights included in the units. The Class A ordinary shares, warrants, and rights that are separated are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “SSAC,” “SSAC ...

SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). “As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth,” said Dr. Xian-Ming Zeng, Chi ...

Core Viewpoint - Navan, Inc. is facing a class action lawsuit related to its October 31, 2025 IPO, with investors having until April 24, 2026, to file a lead plaintiff motion [1]. Group 1: Legal Action - The Portnoy Law Firm is advising Navan investors to join a class action lawsuit concerning securities purchased during the IPO [1]. - Investors can contact attorney Lesley F. Portnoy for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Defendants - The lawsuit alleges that the defendants made false and misleading statements regarding Lakeland's business operations, particularly concerning issues with the Pacific Helmets and Jolly businesses [3]. - Specific allegations include significant shipping delays, production issues, and a slower rollout of new products, which were not disclosed [3]. - The defendants are accused of overstating the financial impact of these businesses and the overall strength of their operations [3]. - The lawsuit claims that Lakeland's financial results were deteriorating due to tariff-related challenges and other operational issues [3]. - It is alleged that the defendants' financial guidance was unreliable due to these issues, leading to materially false public statements [3].

LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lakeland Industries, Inc., (“Lakeland” or the "Company") (NASDAQ: LAKE) investors off a class action on behalf of investors that bought securities between December 1, 2023 and December 9, 2025, inclusive (the “Class Period”). Lakeland investors have until April 24, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss th ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on March 9, 2026, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Ardent Health securities between July 18, 2024, and November 12, 2025, may be eligible for compensation through a class action lawsuit [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is March 9, 2026, which is crucial for those wishing to represent other class members [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing their capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable and the processes used to determine their collectability [4]. - Defendants claimed to employ an active monitoring process for accounts receivable, which was later revealed to be inaccurate, as they did not primarily rely on detailed reviews [4]. - The firm also misrepresented its professional malpractice liability insurance coverage, which was insufficient to cover claims, particularly in the New Mexico market [4].